Cancer and hypertension: a potential for crosstalk?
Epidemiological evidence, particularly from prospective studies, points to the possibility that there is a weak but significantly increased risk of cancer in hypertension. Many classes of drugs have been accused of increasing the risk of cancer yet these studies were case-controlled and did not withstand prospective randomized evaluation. As our understanding of cellular biology and our capacity to dissect genetic components of complex diseases progress, we realize that many pathophysiological pathways are actually quite similar in distinct disorders such as cancer and hypertension. A question can therefore be asked: are the increased risks of cancer and hypertension not related to fundamentally shared pathways, since both disorders reflect proliferative abnormalities? We propose a search for such shared pathways.
Hamet
P
P
Centre de Recherche-CHUM, Montreal, Quebec, Canada.
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D009369:Neoplasms / Q000139:chemically induced / Q000503:physiopathology*; D012307:Risk Factors
D000959:Antihypertensive Agents